All In Biotech

Drug Trial Radar · NCT02847598

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations

Last checked: Nov 19, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

264

Actual

Start

Oct 20, 2016

Primary completion

Aug 28, 2019

Study completion Nov 18, 2019

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jul 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the efficacy of BIIB059 (litifilimab) in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement (Part A), and in participants with active cutaneous lupus erythematosus (CLE) (Subacute cutaneous lupus erythematosus (SCLE) or chronic CLE, including discoid lupus erythematosus (DLE)) with or without systemic manifestations (Part B). The secondary objective is to evaluate additional efficacy parameters of BIIB059 in reducing SLE/CLE disease activity, pharmacokinetic parameters, safety and tolerability of BIIB059 (Parts A and B).

Conditions

  • Systemic Lupus Erythematosus
  • Active Cutaneous Lupus Erythematosus

Interventions

  • BIIB059 (litifilimab)Drug

    Administered as specified in the treatment arm.

  • PlaceboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24Time frame: Baseline to Week 24
  2. Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 16Time frame: Baseline to Week 16

Locations

128 sites in 12 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group LLC

    Anniston, Alabama

  • Arizona Arthritis & Rheumatology

    Phoenix, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • TriWest Research Associates, LLC

    El Cajon, California

  • Tien Q Nguyen MD Inc

    Fountain Valley, California

  • MD Med Corp

    Hemet, California

  • Universtiy of California, Irvine

    Irvine, California

  • The Regents of the University of California

    La Jolla, California

  • Purushotham Akther & Rosan Kotha, MD Inc.

    La Mesa, California

  • Dermatology Reserach Associates

    Los Angeles, California

  • University Clinical Trials

    San Diego, California

  • Richard Barthel, MD

    Santa Barbara, California

  • Robin K. Dore, MD, Inc.

    Tustin, California

  • Inland Rheumatology Clinical Trials Inc.

    Upland, California

  • Nazanin Firooz, MD Inc.

    West Hills, California

  • Denver Arthritis Clinic

    Denver, Colorado

  • Medical Faculty Associates, Inc.

    Washington D.C., District of Columbia

  • Howard University Hospital

    Washington D.C., District of Columbia

  • Washington DC VA Medical Center

    Washington D.C., District of Columbia

  • Clinical Research of West Florida- Corporate

    Clearwater, Florida

  • Medical Research Center Of Miami

    Miami, Florida

  • Lakes Research, LLC

    Miami Lakes, Florida

  • Omega Research Consultants

    Orlando, Florida

  • Compass Research, LLC

    Orlando, Florida

  • DMI Research, Inc.

    Pinellas Park, Florida

  • Advanced Medical Reserarch, PC

    Sandy Springs, Georgia

  • Advanced Clinical Research

    Boise, Idaho

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Davis Group, LTD

    Las Vegas, Nevada

  • Valley Hospital

    Ridgewood, New Jersey

  • Institute for Rheumatic & Autoimmune diseases, Overlook Medical Center

    Summit, New Jersey

  • Albuquerque Center For Rheumatology

    Albuquerque, New Mexico

  • North Shore/Long Island Jewish PRIME

    Great Neck, New York

  • Univeristy of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Joint and Muscle Research Institute

    Charlotte, North Carolina

  • American Health Research, Inc.

    Charlotte, North Carolina

  • Medication Management, LLC

    Greensboro, North Carolina

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.